Resolving the daratumumab interference with blood compatibility testing

Transfusion

Volumn 55, Issue 6, 2015, Pages 1545-1554

  Chapuy, Claudia I ^a   Nicholson, Rachel T ^a   Aguad, Maria D ^a   Chapuy, Bjoern ^b   Laubach, Jacob P ^b   Richardson, Paul G ^b   Doshi, Parul ^c   Kaufman, Richard M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Janssen R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DARATUMUMAB; DITHIOTHREITOL; IMMUNOGLOBULIN IDIOTYPE; REAGENT; TRYPSIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD BANK; BLOOD COMPATIBILITY; BLOOD SAMPLING; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA; BLOOD GROUP TYPING; CROSS REACTION; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MULTIPLE MYELOMA; SEROLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; BLOOD GROUPING AND CROSSMATCHING; CROSS REACTIONS; DITHIOTHREITOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; MULTIPLE MYELOMA; SEROLOGIC TESTS; TRANSFECTION;

EID: 84931577511     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13069     Document Type: Article

References (15)

1. de Weers M, Tai YT, van der Veer MS, et al., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.
2. Plesner T, Lokhorst H, Gimsing P, et al., Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. ASH Annual Meeting Abstracts 2012; 120: 73.
3. Lokhorst HM, Plesner T, Gimsing P, et al., Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. ASCO Meeting Abstracts 2013; 31 (Suppl 15): 8512.
4. Deaglio S, Canella D, Baj G, et al., Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res 2001; 25: 227-35.
5. Mehta K, Shahid U, Malavasi F,. Human CD38, a cell-surface protein with multiple functions. FASEB J 1996; 10: 1408-17.
6. Zocchi E, Franco L, Guida L, et al., A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun 1993; 196: 1459-65.
7. Albeniz I, Demir O, Türker-Sener L, et al., Erythrocyte CD38 as a prognostic marker in cancer. Hematology 2007; 12: 409-14.
8. Berthelier V, Laboureau J, Boulla G, et al., Probing ligand-induced conformational changes of human CD38. Eur J Biochem 2000; 267: 3056-64.
9. Guida L, Franco L, Zocchi E, et al., Structural role of disulfide bridges in the cyclic ADP-ribose related bifunctional ectoenzyme CD38. FEBS Lett 1995; 368: 481-4.
10. Roback JD, Grossman BJ, Harris T, et al., Technical manual. 17th ed. Bethesda (MD): AABB; 2011.
11. Judd WJ, Johnson ST, Storry JR., Judd's methods in immunohematology. 3rd ed. Bethesda (MD): AABB; 2008.
12. Chapuy B, McKeown MR, Lin CY, et al., Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013; 24: 777-90.
13. Zhao YJ, Lam CM, Lee HC,. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal 2012; 5: ra67.
14. Kontani K, Nishina H, Ohoka Y, et al., NAD glycohydrolase specifically induced by retinoic acid in human leukemic HL-60 cells. Identification of the NAD glycohydrolase as leukocyte cell surface antigen CD38. J Biol Chem 1993; 268: 16895-8.
15. Reid ME, Lomas-Francis C, Olsson ML., The blood group antigen facts book. 3rd ed. Waltham (MA): Academic Press; 2012.